The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Herceptin: From the Bench to the Clinic
Abstract
Polypeptide growth factors play important roles in both normal and pathological development of the breast. Such growth factors promote cell proliferation, motility, and invasiveness of epithelial c...
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Due to the low expression level of HER2, anti-HER2 monoclonal antibodies were ineffective for osteosarcoma patients with HER2-positive [104].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [104]
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Replacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,039
Baselga, J. M., Norton, L., Albanell, J., Kim, Y. M., & Mendelsohn, J. M. (1998) · PubMed · Cited by 996
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 971
Petit, A. M. V., Rak, J. W., Hung, M., Rockwell, P., Goldstein, N. I., FENDLY, B. M., & Kerbel, R. S. (1997) · Europe PMC (PubMed Central) · Cited by 836
Research works printed but not linked: 5
- 10.1128/mcb.9.3.1165-1172.1989 · doi:10.1128/mcb.9.3.1165-1172.1989 · Paper page
- Cobleigh M. A., Vogel C. L., Tripathy N. J., et al. Efficacy and Safety of Herceptin (humanized Anti-HER-2 Antibody) as a Single Agent in 222 Women with HER-2 Overexpression Who Relapsed Following Chemotherapy for Metastatic Breast Cancer [Abstract 376]. Proc. Am. Soc. Clin. Oncol. 1998; 16: 376
- Vogel C. L. Cobleigh M. A. Tripathy D. et al. Efficacy and Safety of Herceptin (Trastuzumab Humanized Anti-HER-2 Antibody) as a Single Agent in First-Line Treatment of HER-2 Overexpressing Metastatic Breast Cancer (HER−2+/MBC) [Abstract 23]. 21st Annual San Antonio Breast Cancer Symposium. San Antonio TX 1998
- Norton L., Slamon D., Leyland-Jones B., Wolter J., Flaming T., Eirmann W., Baselga J., Mendelsohn J., Bajamonde A., Ash M., Shak S. Overall Survival Advantage to Simultaneous Chemotherapy Plus the Humanized Anti-HER2 Monoclonal Antibody Herceptin in HER2-overexpressiong Metastatic Breast Cancer [Abstract 483]. Proc. Am. Soc. Clin. Oncol. 1998; 18: 127
- Hudis C. Seidman A. Paton V. et al. Characterization of Cardiac Dysfunction in the Herceptin (Trastuzumab) Clinical Trials [Abstract 24]. 21st Annual San Antonio Breast Cancer Symposium. San Antonio TX 1998
Cited by
Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
Lambert, J. M., & Chari, R. V. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500766w · Cited by 545
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“Due to the low expression level of HER2, anti-HER2 monoclonal antibodies were ineffective for osteosarcoma patients with HER2-positive [104].”
BackgroundAhmed, N., Salsman, V. S., Yvon, E., Louis, C. U., Perlaky, L., Wels, W. S., Dishop, M. K., Kleinerman, E. E., Pule, M., Rooney, C. M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.133 · Cited by 215
Rowinsky, E. K. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104433 · Cited by 178
Metadata
- Authors
- Colomer, R., Shamon, L. A., Tsai, M. S., & Lupu, R.
- Affiliations
- Hospital Universitario 12 De Octubre (ES)
- Lawrence Berkeley National Laboratory (US)
- ORCID
- Venue
- Cancer Investigation
- Publisher
- Informa UK Limited
- Published
- 2001-01
- Volume
- 19
- Issue
- 1
- Pages
- 49-56
- ISSN
- 0735-7907 (ISSN-L)
- 1532-4192
- OpenAlex
- W2014184151
- Cited by
- 43
- References
- 40
- Citations by year
- 2025: 2 · 2024: 1 · 2020: 1 · 2015: 2 · 2014: 1 · 2013: 2 · 2012: 1
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Investigation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- trastuzumab, HER2/neu, peptide growth factors, breast cancer, breast development, cell proliferation, tumor invasion
- MeSH terms
- Trastuzumab, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Clinical Trials as Topic, Female, Heart, Humans, Neoplasm Metastasis, Erb-b2 Receptor Tyrosine Kinases, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.